Synthis Therapeutics is an innovative biotech company focused on developing a novel therapeutic platform aimed at enhancing immune function to combat advanced cancer. The company's approach centers on targeting the TGF-β pathway, which is known to be highly immunosuppressive in various cancers. By selectively inhibiting this pathway, Synthis aims to create safer and more effective therapies that leverage the body’s own immune system to eliminate metastatic cancer cells. This strategy is designed to improve patient outcomes and survival rates by restoring the immune response against tumors.

The team at Synthis Therapeutics comprises experienced tumor immunologists who are dedicated to advancing the science of immuno-oncology. Their commitment to innovation is reflected in their early-stage development of targeted therapies, with a lead drug candidate, SYN101, already optimized for in vivo tumor clearance. The company has received recognition and support through various awards and accelerator programs, underscoring its potential impact in the field of cancer treatment. Through their groundbreaking work, Synthis Therapeutics is positioned to make significant contributions to the future of cancer therapeutics.

United States

Dynamic therapeutics immuno-oncology startup in NYC. Synthis’s team is a talented group of scientists with a groundbreaking idea to improve patient care and outcomes. As long-standing tumor immunologists, the team is passionate about the science and therapeutic power behind restoring immune function in cancer patients.

Synthis Therapeutics

Company Details